I
n the intensive care unit (ICU), there are a number of commonly used medications that alter the immune system and cytokine activity, even though this is not their intended action, in what has been called "unintended immunomodulation" (1) . Haloperidol has been used for many years to manage agitation in mechanically ventilated ICU patients, and it is the recommended drug for treatment of delirium in the ICU (2, 3) . In addition to reducing agitation and delirium, haloperidol inhibits secretion of proinflammatory cytokines (4, 5) and improves survival in an experimental model of sepsis in rats (6) . In view of these observations, we hypothesized that treatment with haloperidol would improve survival of critically ill patients. Accordingly, we examined the relationship between haloperidol use and hospital mortality in mechanically ventilated ICU patients at a large tertiary care academic medical center.
MATERIALS AND METHODS
Patients. For our cohort, we selected all patients whose initial duration of mechanical ventilation was Ͼ48 hrs from all ICU admissions during the period from July 1, 2000, to June 30, 2001 , at the University of Pittsburgh Medical Center, a hospital with Ͼ120 ICU beds caring for adult medical, surgical, trauma, neurologic, and solid-organ transplant patients. We chose to study patients mechanically ventilated for Ͼ48 hrs to be certain that we were selecting a truly "critically ill" patient population, one likely to have a significant acute inflammatory response, as opposed to routine postoperative patients or others admitted for short ICU stays without severe illness. Patients who never received haloperidol at any time during their hospital stay were classified as being in the "no-haloperidol" group. Those who first received haloperidol within 2 days of initiation of mechanical ventilation were classified as being in the "haloperidol" group based on the hypothesis that for haloperidol to affect outcome, treatment with it must be initiated early in the course of mechanical ventilation.
Clinical Databases Utilized. We obtained information from several computerized databases, including hospital billing records and Eclipsys, a database containing the following prospectively collected data for all ICU patients: demographics, admission diagnosis, physiologic data, laboratory data, interventions (medications, fluids, mechanical ventilation, feeding, oxygen, renal replacement, transfusions), and nursing and respiratory therapy notes. To preserve patient confidentiality, all data were de-identified and linked by an honest broker. The data were cleaned (purged of inconsistent and/or nonsense values), organized, and merged to create files for the analysis. Extensive computer programming was then used to create complex variables (e.g., presence of organ dysfunction) from detailed physiologic data. Data were assembled into a relational database using Microsoft FoxPro 6.0.
Statistical Analyses. For our primary analysis, we examined differences in hospital mortality between the haloperidol and nohaloperidol groups. We generated KaplanMeier survival curves and used the log-rank statistic to test the null hypothesis that the two curves were identical. Univariate comparisons between groups were conducted for baseline patient characteristics and outcomes of interest using chi-square or Fisher's exact tests, as appropriate, for categorical measures and two-sample Wilcoxon's tests for continuous measures. Multivariable logistic regression and Cox proportional hazards models using stepwise selection with p Յ .10 as criteria for entry into the models were used to compare differences in mortality between groups, adjusting for the following potential confounders: admission type (medical vs. surgical), admission diagnosis, ICU type (general medical, general surgical, nonsurgical cardiac, cardiothoracic/vascular, trauma, neurologic, or abdominal solid-organ transplant ICU), age, gender, race, severity of illness (Simplified Acute Physiology Score II) (7), baseline and day 2 degree of organ dysfunction (Sequential Organ Failure Assessment) (8) , and number and type of comorbidities (Charlson-Deyo) (9). To explore potential dose-response characteristics, we also examined differences in hospital mortality stratified by tertiles of mean daily haloperidol dose (0.5-5.0 mg/day [low dose], 5.1-12.5 mg/day [medium dose], and Ͼ12.5 mg/day [high dose]). In a secondary analysis, we repeated these steps comparing the nohaloperidol group with the group of patients who received haloperidol at any time during mechanical ventilation. All data analyses were performed using SAS 8.02 (SAS Institute, Cary, NC) and assuming a statistical significance at p Ͻ .05. The institutional review board approved this study.
RESULTS

Patient
Characteristics. There were 83 and 906 patients in the haloperidol and no-haloperidol groups, respectively. On the day of intubation, there were no significant differences between groups with respect to age, race, severity of illness, degree of organ dysfunction, number of comorbidities, or admission type (Table  1) . Patients treated with haloperidol were more likely to be male (67.5% vs. 55.2%; p ϭ .031), to have severe liver disease (18.1% vs. 8.1%; p ϭ .002), and to be admitted for nonoperative trauma (12.0% vs. 5.3%; p Ͻ .01) and less likely to have uncomplicated diabetes (7.2% vs. 15.9%; p ϭ .04). The groups were evenly distributed across the various types of ICUs, with the exception that those treated with haloperidol were more likely to be in the transplant ICU (31.3% vs. 14.5%; p Ͻ .001) and less likely to be in the neurologic ICU (2.4% vs. 11.4%; p ϭ .01). Patients in the haloperidol group received a mean (ϮSD) daily dose of 11.5 (Ϯ11.6) mg for 3.5 (Ϯ4.6) days, with 31, 26, and 26 patients in the low (0.5-5.0 mg/day), medium (5.1-12.5 mg/day), and high (Ͼ12.5 mg/day) mean daily haloperidol dose groups, respectively.
Univariate Analyses. Patients who received haloperidol had significantly lower hospital mortality than those who did not receive the drug (20.5% vs. 36.1%; p ϭ .004). As compared with the no-haloperidol group, hospital mortality was signif- (Fig. 1) .
Multivariable Analyses. All variables listed in Table 1 were eligible for inclusion as potential confounders in the multivariable models. Those that were associated with hospital mortality (logistic regression model) or survival (Cox proportional hazards model) at a significance level of p Յ .10 were entered into the models in a stepwise fashion and retained if they remained significant at that level ( Table 2) . After adjusting for these potential confounders, patients who received haloperidol had significantly lower odds of hospital mortality (adjusted odds ratio, 0.35; 95% confidence interval, 0.18 -0.69; p ϭ .0022) and rate of deaths (adjusted hazard ratio, 0.39; 95% confidence interval, 0.30 -0.50; p ϭ .0002) in the logistic regression and Cox proportional hazards models, respectively. Similar results were obtained for both models when we compared no-haloperidol patients with those who received haloperidol at any time during mechanical ventilation (n ϭ 189) (results not shown).
DISCUSSION
We believe we are the first to implicate that treatment with haloperidol is associated with improved survival in mechanically ventilated ICU patients. In addition, the data seem to indicate a possible doseresponse relationship. Although groups were similar at baseline and we adjusted for potential confounders, it remains possible that unmeasured differences between groups, including indication bias, could account for this association. Nevertheless, these results are provocative.
We considered three possible mechanisms to explain the apparent therapeutic effect of haloperidol. First, treatment with haloperidol might avoid excess sedative and analgesic use, which has been associated with prolonged duration of mechanical ventilation and ICU length of stay (10 -14) . While we were not able to determine whether treatment with haloperidol was associated with a reduction in the use of these medications, we did note that there were no differences in the duration of mechanical ventilation or the ICU length of stay between groups. Sec- Figure 1 . Haloperidol use vs. survival to hospital discharge. This Kaplan-Meier plot compares survival to hospital discharge for the no-haloperidol and haloperidol groups. a All variables listed in Table 1 were eligible for inclusion in the multivariable models. Those associated with hospital mortality (logistic regression model) or survival (Cox proportional hazards model) at significance level p Յ .10 were entered into the models in a stepwise fashion and retained if they remained significant at that level.
ond, it has been postulated that central nervous system dysfunction contributes to the pathogenesis of severe illness through impaired central nervous system-mediated antiinflammatory mechanisms and interrupted central-peripheral signaling (15) (16) (17) . Stabilization of cognitive function with haloperidol may have reduced or reversed these negative effects. Third, in vitro studies indicate that haloperidol inhibits the release of proinflammatory cytokines from immunostimulated monocytes and macrophages (4, 5) . Although we did not measure cytokine levels, treatment with haloperidol may have reduced the cytokine storm associated with critical illness, thereby reducing multiple organ dysfunction and improving survival.
The key limitations of this study stem from its retrospective observational cohort design. The data obtained are hypothesis generating and, like any observational study, not intended to establish a causal link between exposure and outcome. As such, our findings should be confirmed in a randomized, controlled trial before being applied to routine patient care. Due to the retrospective nature of this study, we were not able to determine why patients received haloperidol. In our ICUs, haloperidol is typically used to manage agitation and delirium. None of our attending physicians report using it for its antiinflammatory effects. With Ͼ50 different attending physicians staffing our ICUs and no standard protocol governing its use, the use of haloperidol and other medications for agitation and delirium management, such as benzodiazepines or propofol, is variable and likely to be somewhat random. Despite similar baseline characteristics and adjustment for potential confounders, the possibility of indication bias remains. However, it is unclear whether indication bias would have narrowed or widened the observed differences in mortality. For example, patients receiving haloperidol may have been more likely to be awake and agitated yet cognitively intact and, therefore, healthier or awake and delirious and, therefore, sicker.
There are a number of potential risks of treatment with haloperidol, including the development of extrapyramidal side effects, neuroleptic malignant syndrome, and QT-interval prolongation leading to torsades de pointes. Because the occurrence of these side effects is not documented in the clinical databases used for this study, we could not determine whether or how often they occurred. Given the observation that mortality was lower in the haloperidol group, it seems unlikely that significant, life-threatening adverse events occurred. Even so, future studies should closely monitor the occurrence of these important adverse events.
CONCLUSION
Treatment with haloperidol during mechanical ventilation was associated with significantly lower hospital mortality for mechanically ventilated ICU patients. Because of the observational nature of this study and the potential risks associated with haloperidol use, these findings should be confirmed in a prospective, randomized, placebo-controlled trial before being applied to routine patient care. 
